A leading Abu Dhabi-based technology company, Group 42 or G42 has joined forces with Rafael Advanced Defense Systems, Rafael and Israel Aerospace Industries (IAI) to collaborate in the field of research and development of effective ways to combat SARS CoV-2, the coronavirus. The announcement was made today that G42 has signed Memoranda of Understanding with the two leading Israeli technology companies.

The signing ceremony was held via video conferencing in which executives of each company participated.

The event was also taken as an opportunity to discuss methods of capitalizing their individual expertise and technologies to develop revolutionary cutting edge solutions and medical initiative for benefit of the people of UAE and Israel, as well as the humanity.

“At G42, we embrace international cooperation as a way to develop new and innovative technological solutions for the public good. The UAE has led by example in the global collaborative effort to defeat the Covid-19 pandemic, and our company is privileged to follow the lead and share resources and expertise with Rafael and IAI for such a significant cause”, CEO of G42 said.

This collaborative initiative has brought together the leading and most active players in the response against Covid-19. They aim to leverage their knowledge, human and technological assets as well as other resources that can act as a catalyst to deliver the required breakthrough for safeguarding public health and supporting global fight against the Covid-19 pandemic.

G42 has led the fight against Covid-19 since the beginning of pandemic. The company has an upper hand due to its Artificial intelligence driven genomics. This has also helped the company to partner with UK’s Oxford Nanopore Technologies to help in “end-to-end detection technology with ultra-high throughput to screen en masse”.

G42 is also undertaking the world’s first phase III clinical trial of COVID-19 inactivated vaccine. This is being done under the supervision of Department of Health of Abu Dhabi.

 WAM